What the First Findings Suggest

Early inspection records from February 2026 provide a first look at how FDA investigators are applying the new Quality Management System Regulation (QMSR) in practice. While only a small number of inspections have occurred so far, the findings suggest that inspectors are already evaluating quality systems using an ISO 13485–aligned framework. Unlike traditional QSR inspections, where observations were typically documented in narrative form on a Form FDA-483, the early QMSR records map inspection findings directly to specific ISO-aligned requirements. This clause-level structure resembles an ISO audit approach and reflects the FDA’s effort to align device inspections more closely with international quality system standards.

The deficiencies identified so far will look familiar to experienced regulatory and quality professionals. Early findings involve issues such as incomplete quality system documentation, weaknesses in design and development controls, gaps in corrective action processes, and inconsistent operational recordkeeping. Another recurring theme is the integration of risk management throughout the quality system, a key expectation under ISO 13485 and the QMSR framework. Several inspections noted that organizations had not yet fully incorporated risk-based thinking into quality system processes such as production controls, supplier management, and corrective action.

The early takeaway is that QMSR inspections are not necessarily identifying entirely new types of compliance problems. Instead, investigators appear to be evaluating traditional quality system requirements through a more structured, system-level lens consistent with ISO 13485. As more inspections occur under QMSR, these early patterns will become clearer. For manufacturers, the message remains straightforward: a well-implemented and well-documented quality management system, one that integrates risk management and maintains strong process controls, remains the best preparation for FDA inspection.

This is a summary of an article published by Medical Devices and Pharma. Read the entire article here.